Search

Summary: Aim: It is not clear whether treatment by vascular endothelial growth factor (VEGF) gene transfer can improve myocardial ischemia through a proangiogenesis mechanism and is effective against coronary artery disease (CAD). We aimed to perform a systematic review and meta‐analysis of randomized controlled trials (RCTs) that compared VEGF gene therapy and standard treatments in CAD. Methods: We systematically searched the PubMed, Embase, and Cochrane databases and relevant references for RCTs (published up to May 2018; no language restrictions) and performed meta‐analysis using both fixed and random effects models. Our primary outcome measures were mortality and serious cardiac events. The secondary outcome measures were follow‐up left ventricular ejection fraction (LVEF), change in LVEF (ΔLVEF), and angina outcomes. The registration number is CRD42017058430. Results: Of 524 identified studies, 14 were eligible and were included in our analysis. At a mean follow‐up of 6 months, VEGF gene therapy demonstrated a decreased risk of serious cardiac events (11.7% vs 21.2%, relative risk: 0.56; 95% confidence interval (CI): 0.37, 0.84; P = 0.005) and a slight improvement in follow‐up LVEF (weighted mean difference: 1.95; 95%CI: 1.28, 2.62). Furthermore, VEGF gene therapy using adenoviral vectors showed more potential benefit in terms of the risk of serious cardiac events, ΔLVEF, and Canadian Cardiovascular Society angina class. Nevertheless, mortality and angina frequency scores were not different. Conclusions: Vascular endothelial growth factor gene therapy appears to be safe and effective regarding serious cardiac events, with greater benefit when using adenoviral vectors. This meta‐analysis highlights the need for further exploration in these areas. [ABSTRACT FROM AUTHOR]

To evaluate the efficacy and safety of liraglutide in patients with Type 2 Diabetes Mellitus (T2DM) complicated with Coronary Artery Disease (CAD), we searched PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Chinese VIP Information (VIP), Wanfang Database and Chinese Biomedical Literature database (CBM) for relevant randomized controlled trials (RCTs) from inception to 7 October 2020. A total of 18 RCTs including 1557 patients with T2DM complicated with CAD were included. Meta-analysis revealed liraglutide reduced hemoglobin A1c (HbA1c) (WMD = −0.67; 95% CI[−0.94 to −0.39]; P < 0.00001), fasting plasma glucose (FPG) (WMD = −0.80; 95% CI[−1.06 to −0.54]; P < 0.00001) and 2 h plasma glucose (2hPG) (WMD = −1.64; 95% CI[−2.12 to −1.16]; P ＜0.00001); improved left ventricular ejection fraction(LVEF) (WMD = 4.79; 95% CI[4.08–5.51]; P < 0.00001), left ventricular end-diastolic diameter (LVEDD) (WMD = −5.70; 95% CI[−6.67 to −4.72]; P ＜0.00001), E/A (WMD = 0.13; 95% CI[0.11–0.14]; P < 0.00001) and left ventricular posterior wall thickness (LVPWT) (WMD = −1.86; 95% CI[−2.16 to −1.55]; P < 0.00001); reduced total cholesterol (TC) (WMD = −0.48; 95% CI[−0.56 to −0.39]; P < 0.00001), triglycerides (TG) (WMD = −0.42; 95% CI[−0.59 to −0.26]; P < 0.00001), low-density lipoprotein cholesterol (LDL-C) (WMD = −0.41; 95% CI[−0.55 to −0.26]; P < 0.00001), and increased high-density lipoprotein cholesterol (HDL-C) (WMD = −0.19; 95% CI[0.13–0.24]; P = 0.0005). As for safety assessment, liraglutide did not increase the incidence of hypoglycemia (OR = 0.75, 95% CI[0.32–1.77], P = 0.51) and gastrointestinal (OR = 1.15, 95% CI[0.72–1.85], P = 0.55) events. Consequently, liraglutide had favorable effects on blood glucose, cardiac function, lipid profile and an acceptable safety profile. [Display omitted] • Little is known about the cardioprotective effects of antidiabetic drugs. • Liraglutide significantly reduced blood glucose, improved lipid metabolism. • Liraglutide protected cardiac function in T2DM patients complicated with CAD. • Liraglutide prevented ventricular remodeling in T2DM patients complicated with CAD. • Liraglutide showed no increased risk in gastrointestinal and hypoglycemia events. [ABSTRACT FROM AUTHOR]